Crinetics Pharmaceuticals Stock Last Dividend Paid

CRNX Stock

USD 56.06 0.97 1.70%

Crinetics Pharmaceuticals fundamentals help investors to digest information that contributes to Crinetics Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Crinetics Stock. The fundamental analysis module provides a way to measure Crinetics Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crinetics Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Crinetics Pharmaceuticals Company Last Dividend Paid Analysis

Crinetics Pharmaceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

Crinetics Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for Crinetics Pharmaceuticals is extremely important. It helps to project a fair market value of Crinetics Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Crinetics Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crinetics Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crinetics Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue
Total Assets		0.5	0.95	-0.17	-0.98	0.78	-0.81	0.95	-0.81	0.83	0.86	-0.81	1.0	0.94	0.98	0.72	1.0	1.0	0.9	-0.79	0.98	0.83
Total Stockholder Equity	0.5		0.24	0.48	-0.47	0.06	-0.83	0.73	-0.83	0.14	0.8	-0.83	0.47	0.74	0.48	0.02	0.45	0.46	0.7	-0.07	0.48	0.44
Net Tangible Assets	0.95	0.24		-0.39	-0.93	0.84	-0.63	0.82	-0.63	0.92	0.67	-0.63	0.97	0.81	0.93	0.83	0.97	0.97	0.75	-0.87	0.93	0.75
Net Debt	-0.17	0.48	-0.39		0.09	-0.22	-0.23	0.07	-0.23	-0.41	0.27	-0.23	-0.2	0.07	-0.14	-0.43	-0.23	-0.21	0.24	0.44	-0.14	0.26
Retained Earnings	-0.98	-0.47	-0.93	0.09		-0.81	0.78	-0.93	0.78	-0.77	-0.88	0.78	-0.98	-0.92	-0.99	-0.67	-0.97	-0.98	-0.92	0.8	-0.99	-0.9
Accounts Payable	0.78	0.06	0.84	-0.22	-0.81		-0.39	0.65	-0.39	0.86	0.51	-0.39	0.79	0.65	0.8	0.9	0.8	0.79	0.59	-0.92	0.8	0.72
Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39		-0.92	1.0	-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Net Receivables	0.95	0.73	0.82	0.07	-0.93	0.65	-0.92		-0.92	0.71	0.95	-0.92	0.94	1.0	0.93	0.59	0.93	0.94	0.94	-0.66	0.93	0.82
Long Term Debt Total	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92		-0.49	-0.93	1.0	-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Capital Surpluse	0.83	0.14	0.92	-0.41	-0.77	0.86	-0.49	0.71	-0.49		0.48	-0.49	0.85	0.7	0.77	0.97	0.87	0.85	0.54	-0.88	0.77	0.57
Total Liab	0.86	0.8	0.67	0.27	-0.88	0.51	-0.93	0.95	-0.93	0.48		-0.93	0.84	0.96	0.87	0.35	0.81	0.83	0.97	-0.49	0.87	0.85
Short Long Term Debt	-0.81	-0.83	-0.63	-0.23	0.78	-0.39	1.0	-0.92	1.0	-0.49	-0.93		-0.79	-0.91	-0.8	-0.32	-0.77	-0.78	-0.89	0.45	-0.8	-0.73
Total Current Assets	1.0	0.47	0.97	-0.2	-0.98	0.79	-0.79	0.94	-0.79	0.85	0.84	-0.79		0.93	0.98	0.74	1.0	1.0	0.88	-0.81	0.98	0.83
Short Term Debt	0.94	0.74	0.81	0.07	-0.92	0.65	-0.91	1.0	-0.91	0.7	0.96	-0.91	0.93		0.92	0.58	0.92	0.93	0.93	-0.65	0.92	0.81
Common Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92		0.68	0.97	0.98	0.91	-0.82	1.0	0.87
Property Plant Equipment	0.72	0.02	0.83	-0.43	-0.67	0.9	-0.32	0.59	-0.32	0.97	0.35	-0.32	0.74	0.58	0.68		0.76	0.74	0.4	-0.9	0.68	0.47
Net Invested Capital	1.0	0.45	0.97	-0.23	-0.97	0.8	-0.77	0.93	-0.77	0.87	0.81	-0.77	1.0	0.92	0.97	0.76		1.0	0.86	-0.82	0.97	0.81
Net Working Capital	1.0	0.46	0.97	-0.21	-0.98	0.79	-0.78	0.94	-0.78	0.85	0.83	-0.78	1.0	0.93	0.98	0.74	1.0		0.88	-0.81	0.98	0.82
Short Term Investments	0.9	0.7	0.75	0.24	-0.92	0.59	-0.89	0.94	-0.89	0.54	0.97	-0.89	0.88	0.93	0.91	0.4	0.86	0.88		-0.53	0.91	0.93
Deferred Long Term Liab	-0.79	-0.07	-0.87	0.44	0.8	-0.92	0.45	-0.66	0.45	-0.88	-0.49	0.45	-0.81	-0.65	-0.82	-0.9	-0.82	-0.81	-0.53		-0.82	-0.58
Capital Stock	0.98	0.48	0.93	-0.14	-0.99	0.8	-0.8	0.93	-0.8	0.77	0.87	-0.8	0.98	0.92	1.0	0.68	0.97	0.98	0.91	-0.82		0.87
Current Deferred Revenue	0.83	0.44	0.75	0.26	-0.9	0.72	-0.73	0.82	-0.73	0.57	0.85	-0.73	0.83	0.81	0.87	0.47	0.81	0.82	0.93	-0.58	0.87

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict Crinetics Pharmaceuticals

Crinetics Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(37.25)

At this time, Crinetics Pharmaceuticals' Dividend Paid And Capex Coverage Ratio is fairly stable compared to the past year.

Based on the recorded statements, Crinetics Pharmaceuticals has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Earnings Calls Now

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges

All Next

Launch Module

Crinetics Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crinetics Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crinetics Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Crinetics Fundamentals

	Return On Equity	-0.4
	Return On Asset	-0.24
	Operating Margin	(295.25) %
	Current Valuation	4.39 B
	Shares Outstanding	92.74 M
	Shares Owned By Insiders	1.79 %
	Shares Owned By Institutions	94.68 %
	Number Of Shares Shorted	6.94 M
	Price To Earning	(12.03) X
	Price To Book	6.24 X
	Price To Sales	5,004 X
	Revenue	4.01 M
	Gross Profit	(125.49 M)
	EBITDA	(221.51 M)
	Net Income	(214.53 M)
	Cash And Equivalents	408.51 M
	Cash Per Share	7.60 X
	Total Debt	51.73 M
	Debt To Equity	0.01 %
	Current Ratio	15.94 X
	Book Value Per Share	10.30 X
	Cash Flow From Operations	(166.31 M)
	Short Ratio	8.47 X
	Earnings Per Share	(3.70) X
	Target Price	73.29
	Number Of Employees	290
	Beta	0.62
	Market Capitalization	5.2 B
	Total Asset	635.35 M
	Retained Earnings	(653.7 M)
	Working Capital	530.21 M
	Current Asset	44.96 M
	Current Liabilities	2.41 M
	Net Asset	635.35 M

About Crinetics Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Crinetics Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crinetics Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crinetics Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC